89bio - ETNB Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings or view top-rated stocks.

8 brokers have issued twelve-month target prices for 89bio's shares. Their ETNB share price forecasts range from $19.00 to $50.00. On average, they predict the company's stock price to reach $33.25 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price.
View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts.

89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has increased by 33.1% and is now trading at $16.94.
View the best growth stocks for 2023 here.

89bio saw a increase in short interest in February. As of February 28th, there was short interest totaling 5,150,000 shares, an increase of 10.8% from the February 13th total of 4,650,000 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 4.8 days.
View 89bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ETNB earnings forecast.

89bio, Inc. (NASDAQ:ETNB) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by $0.35.

ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco Raymond James SB-1 Equity ETF (RYJ), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Honeywell International (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

89bio trades on the NASDAQ under the ticker symbol "ETNB."

89bio's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (17.71%), Millennium Management LLC (3.08%), Marshall Wace LLP (2.94%), Point72 Asset Management L.P. (2.03%), Two Sigma Investments LP (1.41%) and Citigroup Inc. (1.07%). Insiders that own company stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends.

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETNB stock can currently be purchased for approximately $16.94.

89bio (NASDAQ:ETNB) has a market capitalization of $884.78 million. The company earns $-102,030,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.